Chosen from among 120 applicants, Aptimmune Biologics was selected by The Yield Lab to participate in a nine-month program designed to support emerging ag tech companies.

Aptimmune Biologics is developing and will soon launch innovative autogenous mucosal vaccines to help producers prevent major swine viral diseases.

“We are honored that The Yield Lab has chosen to invest in Aptimmune and to share its business accelerator expertise with us,” says Aaron Gilbertie, CEO of Aptimmune Biologics. “We are among a very select group of emerging ag technology companies that The Yield Lab has selected to invest in and we believe their support and business resources will help us bring new, highly-effective animal health products to market more quickly.”

“Aptimmune is a company with extensive technical expertise, and the vaccine products they are developing have the potential to greatly improve swine health and food production in general,” says Matt Plummer, Principal at The Yield Lab. “The entire Aptimmune team has been tremendous to work with, and we believe the company is deriving value from The Yield Lab business accelerator program.”